Furthermore, PI3KCA mutations and PTEN loss coexist in prostate cancer and cooperate in mouse models to accelerate prostate cancer development and facilitate the progression to castration-resistant metastatic tumors [261]. This evidence concerns the gene PTEN and prostate carcinoma.